title: Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
authors.forename: Antonio
authors.initials: A
authors.lastname: Diaz-Sanchez
authors.forename: Nuria
authors.initials: N
authors.lastname: Rodriguez-Salas
authors.forename: Teresa
authors.initials: T
authors.lastname: Aramendi
authors.forename: Eva
authors.initials: E
authors.lastname: Balbin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000139:chemically induced* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib